lung disease
EpiEndo publishes new data supporting glasmacinal’s potential in COPD
June 13, 2025Medical Communications, Research and Development Chronic Diseases, EpiEndo Pharmaceuticals, Fraunhofer Institute for Toxicology and Experimental Medicine, antimicrobial resistance, chronic obstructive pulmonary disease (COPD), lung disease
EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of …
Bellerophon Therapeutics completes phase 3 study for fibrotic interstitial lung disease drug
May 12, 2023Medical Communications Bellerophon Therapeutics, Cardiology, clinical trial, lung disease
US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed its phase 3 REBUILD study, …
Living in polluted city for ten years increases risk of lung disease as much as pack of cigarettes a day for 29 years
August 14, 2019Research and Development Air pollution, COPD, lung disease, pharma emphysema, public health
Air pollution in cities dramatically increases the risk for and risk of progression of emphysema, a form of chronic obstructive …
Boehringer Ingelheim says new studies underline efficacy of lung disease drug
May 18, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease
Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …
Pfizer gets first approval for rare lung disease
May 29, 2015Sales and Marketing FDA, Pfizer, Rapamune, lung disease
Pfizer’s Rapamune will become the first drug available to treat the very rare lung disease lymphangioleiomyomatosis (LAM) after receiving approval …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
